U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07861425) titled 'Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs' on Sept. 29.
Brief Summary: ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma Metastatic
Hepatocellular Carcinoma Non-Resectable
Intervention:
DRUG: ACE723
Intravenous Administration
Recruitment Status: ...